This week, the South African Health Products Regulatory Authority (SAHPRA) announced that: Given that there is currently no credible evidence to support a therapeutic role for Ivermectin in Covid-19, SAHPRA has decided to terminate the controlled compassionate programme with immediate effect. SAHPRA enabled the programme in response to the demand for access to Ivermectin for human use, which was initiated at the beginning of 2021, after the country had been under lockdown for almost an entire year and was desperate for alternative therapies to treat Covid-19. Prior to the onset of Covid-19, Ivermectin had been used in humans for 35 years and over four billion doses had been administered. In 2015, the two individuals who developed Ivermectin were awarded a Nobel Prize for medicine. However, when Covid-19 came along, Ivermectin was a thorn in the side of the official narrative. Professor Colleen Aldous, a healthcare scientist at UKZNs College of Health Sciences, has valiantly challenged the establishments resistance to Ivermectin throughout the pandemic. After SAHPRAs decision this week, Aldous penned the following article dissecting Ivermectin trials, which credibly evidence the benefits of Ivermectin. Aldous asserts that SAHPRA is wilfully blinded to the totality of the evidence [and] follow only what is fed to them by other reputable national and international bodies. As always, each reader can decide for themselves. Nadya Swart
Pondering SAHPRAs Ivermectin decision
By Professor Colleen Aldous*
On 30 May 2022, SAHPRA shut down their Controlled Compassionate Use Programme for Ivermectin, which they put in place at the end of January 2021. It is not the fact that they have terminated the programme that worries me as much as their reasons for doing so. The compassionate use programme was never going to be permanent, and good housekeeping would require a formal termination. Had their reasons been because no new applications for importation of unregistered Ivermectin products have been received since August 2021. A marked decline in the number of health facilities applying for permission to hold bulk stock was noted after August 2021. No individual named patient applications have been approved since December 2021, and a lack of reporting by the treating healthcare providers of the outcomes achieved was also noted, I would not raise an eyebrow.
But they have said that the latest developments have led to their decision. Lets unpack these from their press release and ponder the scientific integrity of their rationale:
The studies that suggested potential efficacy of Ivermectin in the prevention and treatment of Covid-19 and which motivated the adoption of the programme have since been retracted.
On 25 May 2022, I did a snapshot search on PubMed for all papers published on Ivermectin and Covid-19 or SARS. PubMed is the go-to database for published literature in the medical sciences. My search rendered 317 articles. Of these, 41 studies were carried out in a clinical setting, and two were retracted with retraction notices published. Reading between the lines, I think SAHPRA was referring to the Elgazzar trial, which was included in initial reviews from several authors. Elgazzar has not been heard of again since his study, which was never published beyond preprint format, and had received enormous criticism through the press worldwide, so his work has to be rejected. Nevertheless, most of the meta-analyses that had already been carried out excluded this study, and the results still showed efficacy for various measures of morbidity and mortality.
Another paper that was retracted was Andrew Hills meta-analysis. In January last year, the world was waiting for the promises from Hills work. It was apparently also the Elgazzar study that SAHPRA suggests in their statement, This was due to serious ethical concerns regarding a study on which the meta-analysis heavily relied. At the same time, however, others were also carrying our meta-analyses. The Bryant et al. meta-analysis showed efficacy for Ivermectin even after removing the Elgazzar data but has been ignored. The science of review and meta-analysis has shown me the creeping subjectivism that has come into what is meant to be a very high standard in evidence-based medicine. Right now, I believe the only meta-analysis I can take as truth will be one I am involved in doing.
SAHPRA refers to two 2021 clinical trials that do not support the use of Ivermectin for patients with COVID-19. These are the Malaysian I-Tech study and the TOGETHER trial. Ironically, SAHPRA representatives criticised the literature available in January 2021 as not being credible, yet they base their decisions on these two trials which have been shown to be flawed.
The I-Tech trial was underpowered. Their primary outcome measure was progression to severe disease, a soft outcome that can be subjectively applied. In the study, 52 of 241 patients in the ivermectin arm and 43 of 249 patients (17.3%) in the control group progressed to severe disease. Nevertheless, for other outcomes, Ivermectin clearly showed a trend towards benefit with only four patients on Ivermectin requiring mechanical ventilation occurred vs 10 on placebo, six on Ivermectin requiring intensive care unit admission in vs eight, and three on Ivermectin vs 10 for 28-day in-hospital death.
Whilst their conclusion, the study findings do not support the use of Ivermectin for patients with Covid-19, is true only because a p value of 0.05 was not achieved for the primary outcome, it is misleading as it implies strong evidence against the use. Their Ivermectin arm has an advantage for mortality with a p = 0.09. This means that you can be 91% certain that Ivermectin was effective in preventing mortality in their study. The p value has not done medicine any favour when studies are judged only on this number and not on clinical context.
The TOGETHER trial was designed as a coup de gras to crush the Ivermectin debate. Weeks before its publication, there were press releases internationally stating that the trial found Ivermectin to be ineffective. Since its publication at the end of March, there have been scientists and medical professionals from across the globe who have challenged this trial on grounds of poor design, poor execution and poor reporting of results. Whilst I share the concerns of my colleagues, there is one particular statistic reported in this trial that worries me and that is of the mortality calculated in the placebo group.
Let me explain. There were 679 patients enrolled in the ivermectin and placebo arms respectively. The numbers dropped to 624 and 288 respectively. In the Ivermectin arm, 21 people died out of the 624 who completed the study, and 24 people died out of an unknown number of patients. The researchers clearly did not use the 288 placebo participants who completed the study in the control arm. It appears they may have borrowed placebo participants from other study arms in the broader TOGETHER trial. Why would they do this?
I wrote to the senior author asking the following question for clarity: The placebo group mortality is 24. When I work out the RRR I get the same answer as offered in the paper if I use the ITT (679) number. However, it is not clear to me where the 24 deaths actually come from. How many of the 24 reported deaths in the placebo group occurred among the 288 patients who stayed per-protocol? It is reported how many of the placebo groups hospitalisations occurred in the per-protocol group but not the mortality.
The response from Doctor Edward Mills: Im not interested in this question as its not the correct way to interpret the outcome.
Many scientists from across the globe are incorrectly interpreting the outcome then. In research as we know it, one would work out the mortality in the intervention and the placebo arm, i.e. the 624 and 288. If this was so, then there is a clear survival advantage in the Ivermectin arm with 21/624 and 24/288 deaths in each arm respectively. Clearly there is a new way of calculating mortality in this trial which Dr Mills feels he cannot explain.
On 4 April 2022, Mills wrote to a colleague: I dont understand the psychology of the Ivermectin advocates. They fail to see the positive in this study and just focus on it not being overwhelmingly positive. I actually think it is quite positive. I presented this a couple weeks ago at the NIH Collaboratory Rounds and, if they listened, I advocate that actually, there is a clear signal that IVM works in Covid-19 patients, just that our study didnt achieve significance. In particular, there was a 17% reduction in hospitalisations that would be significant if more patients were added. I really dont view our study as negative and, also in that talk, you will hear me retract previous statements where I had been previously negative. I think if we had continued randomising a few hundred more patients, it would have likely been significant.
There are calls for the TOGETHER trial to be retracted. However, it comes from the New England Journal of Medicine, which appears to be beyond reproach. Ignoring calls for retraction is within their authority. It was also stated that after publication, the data would be made available. Several colleagues have requested the data through the correct channels and have been stonewalled.
The TOGETHER trial has had some success as a coup de grace. SAHPRA refers to the NEMLC and the NICD not supporting Ivermectin. They usually follow what the USA NIH does. The NIH COVID-19 guidelines panel, misled by the TOGETHER trials claims, had no credible scientific basis for its 29 April 2022 changed recommendation on IVM from neutral to negative. Do we have to copycat the West? 47 African nations stood up together in the WHO on 30 May and firmly stated that they would not support WHO reforms. We should be standing up together more frequently against centralised control that may not necessarily have our interests as Africans as primary goals.
In my snapshot analysis of the literature last week, I found lots of data on the safety and efficacy of Ivermectin. Dosages have been worked out based on Mercks own research from the early 2000s. Drug interactions are well known, particularly with Warfarin, side-effects are well documented as being relatively mild and transient. VigiAccess shows 6,558 adverse reactions and 25 deaths for Ivermectin in its decades of use and Remdesiver has 8,763 adverse reactions and 652 deaths since it was introduced three years ago. I will leave the reader to decide how safe or dangerous Ivermectin is.
Yes, it is SAHPRAs obligation to consider all published data, but do they? They make reference only to the two trials and the one meta-analysis from 2021. They are not considering the totality of data. They have ignored all the laboratory and modelling studies that support the use of Ivermectin. They have ignored all the other published meta-analyses that do not fit their argument. And their guiding reputable authorities from the developed world do not always make decisions that are appropriate for us in Africa, so should not be followed without question and depth of thought. Again, I draw attention to our continent standing up against the WHO reforms on 30 May.
The vaccines are not a replacement for Ivermectin, nor vice versa. Ivermectins role is mainly in the early treatment of Covid-19 to prevent progression to severe illness. Colleagues from the USA, SA and Zimbabwe have just had a paper accepted for publication. We show that after Ivermectin is given to a sick patient, their oxygen saturations improve dramatically within 12 hours without oxygen being provided. Having been involved in this research has convinced me of the efficacy and safety of Ivermectin in certain patients at specific times under certain conditions. No large randomised control trial has yet been carried out with appropriate dosages, over the appropriate length of time, and with meals and zinc because Ivermectin is a zinc ionophore.
SAHPRA has a very narrow definition of credible evidence. They are wilfully blinded to the totality of the evidence. They follow only what is fed to them by other reputable national and international bodies. Do they do any research monitoring themselves? They say they will continue to monitor the peer-reviewed, scientific literature regarding the safety and efficacy of Ivermectin. As the public, we should ask them for the evidence that they have started!
Read Also:
The obfuscation of mortality results can be viewed as a crime against humanity Prof Aldous on recent Ivermectin trials
Best of 2021: South Africans have a constitutional right to take Ivermectin to treat Covid-19, says FMF health expert
Best of 2021: SA health regulator gives Ivermectin the red light again! Professor Aldous and Dr Mdladla interrogate
(Visited 7,031 times, 7,031 visits today)
- What Are the 7 Causes of Blindness? - Healthline - June 2nd, 2024
- Blindness and Low Vision | American Foundation for the Blind - June 2nd, 2024
- Eye care, vision impairment and blindness - World Health Organization (WHO) - October 27th, 2023
- CHOROIDEREMIA RESEARCH FOUNDATION EXPANDS RESEARCH SUPPORT INTO NONSENSE MUTATIONS OF A RARE INHERITED RETINAL - EIN News - May 1st, 2023
- Chennai eye hospital ties up with Iceland firm to adopt mathematical algorithm to predict diabetic retinopathy - The Hindu - April 23rd, 2023
- Drug-Resistant Bacteria Tied to Eyedrops Can Spread Person to Person ... - April 7th, 2023
- Prevention of Blindness Week 2023: Mumbai experts explain why you should be concerned about glaucoma and the need for regular eye checkups -... - April 7th, 2023
- Childhood blindness - Wikipedia - February 24th, 2023
- FDA Approves Syfovre (pegcetacoplan injection) for the Treatment of ... - February 24th, 2023
- Human mini brains illuminate path to curing blindness - February 16th, 2023
- Raymond V. Gilmartin: Man with a global vision - February 16th, 2023
- Why Are People So Mad About MrBeast's Blindness Video? - February 16th, 2023
- This heartwarming video of a colorblind boy seeing color for the first time will make you cry - Indiatimes.com - February 16th, 2023
- Blindness (Vision Impairment): Types, Causes and Treatment - February 8th, 2023
- CDC urges people to stop using brand of artificial tears linked to ... - February 8th, 2023
- Health News Roundup: U.S. FDA says India-made eye drop linked to some infections, blindness and one death; China records 3,278 COVID-related deaths... - February 8th, 2023
- I had two strokes at 29 and gone blind -I've been accused of faking my sight loss - Daily Mail - February 8th, 2023
- Blindness and vision impairment - World Health Organization - January 23rd, 2023
- Recovery from blindness - Wikipedia - January 23rd, 2023
- Colour blindness tests, juggling, avoiding glare: A hockey goalkeepeers quest to train his biggest weapon, eyes - The Indian Express - January 23rd, 2023
- But Did You See the Gorilla? The Problem With Inattentional Blindness ... - October 15th, 2022
- Canadians unaware of diseases that lead to blindness, survey says - CTV News Northern Ontario - October 15th, 2022
- A Review of Corneal Blindness: Causes and Management - Cureus - October 15th, 2022
- A cure for blindness may be first product made in space - Freethink - October 15th, 2022
- Is MrBeast trying to cure 1000 people's blindness? - indy100 - October 15th, 2022
- Early detection and management is the key to prevent glaucoma related blindness: Experts - Express Healthcare - October 15th, 2022
- As World Sight Day Nears, River Blindness is Fading - SaportaReport - October 15th, 2022
- Tears of happiness: How curing blindness in Dolakha saved a girls future - City A.M. - October 15th, 2022
- World Sight Day: Orbis, UC Davis team up to train eye care teams from Latin America to fight avoidable blindness - Ophthalmology Times - October 15th, 2022
- Juan Williams: The GOPs epidemic of intentional blindness - The Hill - October 15th, 2022
- Charles pays tribute to Malawi's elimination of disease causing blindness - Express & Star - October 15th, 2022
- Coping with calamity: Former NYT columnist Frank Bruni on blindness and vision, at Morristown book fest keynote - Morristown Green - October 15th, 2022
- Sighting solutions in a world of vision for weavers - The New Indian Express - October 15th, 2022
- Blindfold run raises $40,000 for the MUHC Foundation to support glaucoma care at the MUHC - StreetInsider.com - October 15th, 2022
- MacKenzie Scott Donates $15M to Address the Eyecare Needs of the Impoverished - InvisionMag - October 15th, 2022
- Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts -... - September 20th, 2022
- Treating cataracts before 'critical age' imperative FBC News - FBC News - September 20th, 2022
- GenSight Biologics to Present at Upcoming Industry and Investor Conferences - Business Wire - September 20th, 2022
- Ashton Kutcher battled vasculitis causing blindness, loss of hearing. Know all about the rare condition - India TV News - August 11th, 2022
- Prevent Blindness Is Recognized as a Healthy People 2030 Champion for Supporting the Initiative's Vision - Vision Monday - August 11th, 2022
- Researchers make progress toward a stem cellbased therapy for blindness - Ophthalmology Times - August 11th, 2022
- The strategic blindness of Israel's caretaker government - JNS.org - August 11th, 2022
- UND professor carries the torch for UND studies of visual impairment and blindness - Grand Forks Herald - August 11th, 2022
- Karan Nagrani is using social media to raise awareness about the 'spectrum of blindness' - ABC News - August 11th, 2022
- Vision impairment and blindness related to NCDs: Fong - FBC News - August 11th, 2022
- Strategic blindness of caretaker government - The Jewish Star - August 11th, 2022
- Massachusetts woman blinded by attack working to help others regain sight - WCVB Boston - August 11th, 2022
- Persuasion Film Review: Is Heterogeneous Casting Race-Inclusionary Or Escapist? - Feminism In India - August 11th, 2022
- Is It Time To Start Using Race And Gender To Combat Bias In Lending? - Forbes - August 11th, 2022
- The journey of Kali Yugi started with the mistake of objectives! - Youthistaan - August 11th, 2022
- A 50-State Review of Access to State Medicaid Program Information for People with Limited English Proficiency and/or Disabilities Ahead of the PHE... - August 11th, 2022
- iHealthScreen Completed Prospective Trial of AI-Based Tool for Age-Related Macular Degeneration (AMD) Screening and Submitting the Results to FDA for... - August 11th, 2022
- Vitamin B12: Why You Need It & Foods To Increase Your Vitamin B12 Intake - NDTV - August 11th, 2022
- Jack Levine: Remembering a dad who proved that even in blindness, there can be vision - The Florida Times-Union - June 26th, 2022
- Potion of Blindness | Minecraft Ideas Wiki | Fandom - June 26th, 2022
- Tightening a molecular "zipper" could help prevent hereditary blindness - New Atlas - June 26th, 2022
- What's the Link Between Glaucoma and Dry Eyes? - Healthline - June 26th, 2022
- Lisa Durden's upcoming documentary "Blind Divas" follows Krystle Allen and Naquela Wright-Prevoe, two Black women entrepreneurs, determined... - June 26th, 2022
- Trump election lies may fit legal concept of willful blindness - Chicago Tribune - June 26th, 2022
- Sightsavers relaunches its thematic strategy The Sun Nigeria - Daily Sun - June 26th, 2022
- Trachoma elimination: millions more to benefit from donated azithromycin - World Health Organization - June 26th, 2022
- Dangers of super gonorrhoea from infertility to blindness as global warning issued - Daily Star - June 26th, 2022
- Fifty years of Title IX: What is it, what does it cover and do we still need it? - The Athletic - June 26th, 2022
- How The SMH Got That Rebel Wilson Story So Wrong - Junkee - June 26th, 2022
- The Week That Was: All of Lawfare in One Post - Lawfare - Lawfare - June 26th, 2022
- Why Brad Pitt quit smoking and drinking altogether during the pandemic - BusinessGhana - June 26th, 2022
- Watch your eye - The New Indian Express - June 26th, 2022
- Olivia Brouwer's art is for everyone to see and touch - Hamilton Spectator - June 26th, 2022
- Monkeypox may not mutate as fast as coronaviruses, but that doesn't mean it can't adapt to its new hosts - The Conversation - June 26th, 2022
- Former American Express Foundation President Takes Helm of Signature Theatre - The Chronicle of Philanthropy - June 26th, 2022
- Junk Science Week: Net-Zero Edition John Constable & Debra Lieberman: The energy of nations and the creation of wealth - Financial Post - June 26th, 2022
- Prevent Blindness Provides Educational Information and Resources on the Leading Cause of Vision Loss - WKTN Radio - June 8th, 2022
- Andrea Bocelli health: 'Doctors tried to cure me' - singer's cause of blindness explained - Express - June 8th, 2022
- Editorial: Blindness on Beacon Hill - Boston Herald - June 8th, 2022
- Over 5000 ophthalmologists to take pledge to reduce preventable blindness to 50% by 2025 at the 80th All India Ophthalmological Conference 2022 - APN... - June 8th, 2022
- Children's author Steve Antony raises awareness of colour blindness for The Queen's Platinum Jubilee - Independent Education Today - June 8th, 2022
- NIH study confirms benefit of supplements for slowing age-related macular degeneration - National Institutes of Health (.gov) - June 8th, 2022
- VoxLens: Adding one line of code can make some interactive visualizations accessible to screen-reader users - University of Washington - June 8th, 2022
- Patients with cataracts forced to wait for a year to get NHS surgery during Covid - The Mirror - June 8th, 2022
- Restoring vision by recharging cells' batteries | MUSC | Charleston, SC - Medical University of South Carolina - June 8th, 2022